Abstract:Background: Despite advancements in screening and treatment options for breast cancer (BC), mortality from BC has increased, accounting for 15% of new cancer deaths in the U.S. in 2020. BC is heterogeneous cancer with different molecular subtypes defined by hormone-receptor status, and the prognoses of BC patients differ by their menopausal status in conjunction with their molecular subtypes. Epigenetic dysregulation patterns can serve as principal predictors of BC progression and mortality by capturing these differences in biology that are linked to BC outcomes, leading to personalized treatment plans. In this study, we aimed to detect subtype- or menopausal-specific DNA methylation (DNAm) in BC tumor tissues across the genome that are associated with BC progression or all-cause mortality. Methods: Associations between site-specific DNAm in tumor and BC survival were evaluated using the Illumina Infinium HumanMethylation450 BeadChip array data from the Cancer Genome Atlas participants. Cox proportional hazards models were used in the strata by tumor subtypes and menopausal status, adjusting for age, race, cancer stage, tumor purity, and cell type proportion. Detected site-specific DNAm was further analyzed to identify subtype- or menopausal-specific differentially methylated regions (DMRs) and functional pathways. The validation of the results was carried out on an independent dataset. Results: We identified eight CpG probes that were associated with survival outcomes in subtype- or menopausal-specific manner. Seven probes among women with luminal A subtype were associated with all-cause mortality or progression-free interval (PFI); four probes among women with luminal B were associated with PFI; and five probes among post-menopausal women were associated with PFI. Of them, six probes presented a lower risk of all-cause mortality or BC progression with higher DNAm. The identified DMRs differed by tumor subtype and menopausal status, and a majority of DMRs were driven by several weaker associations in the same direction among proximal loci. Also, we identified subtype- or menopausal-specific functional genomic pathways. Particularly, a pathway of insulin regulation was associated with all-cause mortality and PFI among pre-menopausal women. The detected site-specific probes were validated with consistent directions and magnitudes of effects on prognosis across two independent datasets. Conclusion: We identified subtype- or menopausal-specific DNAm in BC tumor tissues, DMRs, and functional pathways in association with all-cause mortality or BC progression. Our findings warrant future studies with larger independent datasets for replication and functional implications of detected DNAm. Our detected genome-wide-associated-CpG loci could improve prognosis prediction for BC patients, thus contributing to tailored therapeutic regimens. Citation Format: Do Hyun Kim, Alexandra M. Binder, Hua Zhou, Su Yon Jung. Epigenetic signatures in association with breast cancer mortality and prognosis that are specific to tumor subtype and menopausal status [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5706.

Epigenetic study of early breast cancer (EBC) based on DNA methylation and gene integration analysis

Identification of Molecular Markers Associated with the Progression and Prognosis of Endometrial Cancer: a Bioinformatic Study

Microarray-based analysis of whole-genome DNA methylation profiling in early detection of breast cancer.

Identification of Methylation Markers and Differentially Expressed Genes with Prognostic Value in Breast Cancer.

Development of Potential Prognostic Biomarkers Based on DNA Methylation-Driven Genes for Patients with Endometrial Cancer.

DNA Methylation Profiles and Their Diagnostic Utility in BC

Integrative analysis of DNA methylation and gene expression profiles identified potential breast cancer-specific diagnostic markers

Methylation of Immune-Related Genes in Peripheral Blood Leukocytes and Breast Cancer

Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer

Investigating the potential clinical significance of long non-coding RNA 00092 in patients with breast cancer

Identification of potential DNA methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis

Prognostic evaluation of the novel blueprint of DNA methylation sites by integrating bulk RNA-sequencing and methylation modification data in endometrial cancer

Identification of Aberrantly Methylated Differentially Expressed Genes and Associated Pathways in Endometrial Cancer Using Integrated Bioinformatic Analysis

Determination of Genetic and Epigenetic Modifications-Related Prognostic Biomarkers of Breast Cancer: Genome High-Throughput Data Analysis

Abstract 5706: Epigenetic signatures in association with breast cancer mortality and prognosis that are specific to tumor subtype and menopausal status

Identification and Verification of Key Tumor Genes Associated with Diagnosis and Prognosis of Breast Cancer Based on Bioinformatics Analysis

Discovered Key CpG Sites by Analyzing DNA Methylation and Gene Expression in Breast Cancer Samples

Dna Methylation Age Of Paired Tumor-Normal Breast Tissue In Chinese Women With Breast Cancer

Abstract 146: DNA Methylation Age of Paired Tumor-Normal Breast Tissue in Chinese Women with Breast Cancer

DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer